Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BCAX
BCAX logo

BCAX News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BCAX News

Bicara Therapeutics Reports Q4 2025 Financial Results

1d agoseekingalpha

BICARA THERAPEUTICS INC Reports Q4 Net Loss of $37.4 Million; FY2025 Net Loss Totals $138.0 Million

1d agomoomoo

BICARA THERAPEUTICS BEGINS PHASE 3 OF FORTIFI-HN01 KEY TRIAL; INTERIM RESULTS ANTICIPATED BY MID-2027

1d agomoomoo

Bicara Therapeutics Advances Ficerafusp Alfa in Clinical Trials

1d agoNewsfilter

Bicara Therapeutics CEO Sells Stock Options

1d agoFool

Bicara Therapeutics CEO Sells Shares Amid Strong Stock Performance

1d agoNASDAQ.COM

Key Stock Market Movers: Nvidia, Eli Lilly, Alcoa, Coinbase, and Strategic Developments

2d agoBarron's

Bicara CEO Sells Shares Under 10b5-1 Plan

5d agoFool

BCAX Events

03/30 09:10
Stock Futures Modestly Higher as Oil Prices Surge Above $100
Stock futures are modestly higher to start the week, indicating a potential rebound at the open following five consecutive weeks of declines across major indexes. Markets are stabilizing slightly after last week's sustained selloff, but the broader tone remains cautious as energy prices and geopolitical risk continue to dominate.The primary driver remains oil. Crude prices have surged back above $100 and, in some cases, are pushing toward the $110-$120 range as the Middle East conflict expands and supply concerns intensify. Disruptions tied to the Strait of Hormuz and the widening scope of the conflict, including additional regional involvement, are reinforcing expectations of prolonged tight supply.This is feeding into inflation expectations and interest rate outlooks. Markets are increasingly pricing out the likelihood of Federal Reserve rate cuts this year, as higher energy prices complicate the inflation trajectory. The result is continued pressure on equity valuations, particularly in rate-sensitive sectors.Global markets were mixed overnight, with sharp declines in parts of Asia but more stable trading in Europe and U.S. futures. This indicates that investors are beginning to adjust to elevated oil prices rather than reacting to each incremental move.Energy-related stocks are benefiting from higher crude prices, while broader equity markets continue to face headwinds from rising yields and slower growth expectations. Safe-haven demand is also re-emerging at the margins, with some support for assets like gold and the U.S. dollar.In pre-market trading, S&P 500 futures rose 0.79%, Nasdaq futures rose 0.78% and Dow futures rose 0.77%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -iQiyiup 10% after announcing a listing application form submission to the Hong Kong Stock Exchange for Class A ordinary sharesExpediaup 3% after Jefferies upgraded the stock to Buy from Hold with a price target of $300, up from $240CrowdStrikeup 3% after Wolfe Research upgraded shares to Outperform from Peer Perform with a $450 price targetSpireup 1% after entering into an agreement to sell its gas marketing business, Spire Marketing, to Boardwalk Pipelines for $215M in cashUP AFTER EARNINGS -Bicara Therapeuticsup 7%USA Rare Earthup 1%LOWER -Viridian Therapeuticsdown 38% after reporting data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye diseaseSyscodown 6% after announcing it will acquire Jetro Restaurant Depot for total enterprise value of $29.1B
03/30 07:40
Bicara Cash and Securities Decrease to $414.8M
As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8M, compared to $489.7M in cash and cash equivalents as of December 31, 2024. "Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities," said Claire Mazumdar, CEO at Bicara Therapeutics. "The continued advancement of our pivotal FORTIFI-HN01 study, the robust body of clinical data supporting ficerafusp alfa's differentiated profile, and the alternate dosing option for ficerafusp alfa all underscore the significant progress we've made toward transforming outcomes for patients with HPV-negative head and neck cancer. Coupled with our fortified financial position from our recent financing, we are well positioned to execute on our milestones, scale our organization for potential commercialization, if approved, and deliver meaningful value for patients and shareholders throughout the year."

BCAX Monitor News

No data

No data

BCAX Earnings Analysis

No Data

No Data

People Also Watch